Liraglutide (Saxenda) Gets Okay From EU for Obesity Liraglutide (Saxenda) Gets Okay From EU for Obesity
The injectable GLP-1 agonist liraglutide, long available for the treatment of type 2 diabetes, nears the market in Europe for weight loss, hard on the heels of its US approval for the same indication. International Approvals
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Obesity | Victoza | Weight Loss